Lost in Translation: Obstacles to Translational Medicine

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2004 May 20

PMID 15149545

Citations 47

Authors

Stacey P Mankoff

Christian Brander

Soldano Ferrone

Francesco M Marincola

Affiliations

Soon will be listed here.

Abstract

When we launched the Journal of Translational Medicine a few months ago, we were interested primarily in exploring scientific consideration of this discipline. However, as editors of JTM, we have been contacted almost daily to discuss the problems faced by scientists and clinicians around the world who are challenging the traditional boundaries of science and medicine. Through these conversations, we have learned that translational medicine is in fact "lost in translation," inspiring much angst, many promises and some Federal appropriations. However, little has been done to substantively promote this important field. Authoritative reviews on the subject are available to the interested reader 1234567. In this article, we will address JTM's "constituency" to report what we've learned about the obstacles to translational medicine from the myriad of phone conversations and e-mail interactions.

Citing Articles

Investigation into recent advanced strategies of reactive oxygen species-mediated therapy based on Prussian blue: Conceptualization and prospect.

Kwon H, Jung Y, Jeon H, Han H Bioact Mater. 2025; 48:71-99.

PMID: 40034810 PMC: 11874232. DOI: 10.1016/j.bioactmat.2025.01.023.

Efficacy of virtual reality for pain relief in medical procedures: a systematic review and meta-analysis.

Teh J, Pascoe D, Hafeji S, Parchure R, Koczoski A, Rimmer M BMC Med. 2024; 22(1):64.

PMID: 38355563 PMC: 10865524. DOI: 10.1186/s12916-024-03266-6.

Six Recommendations to Build Legitimacy for Translational Research Organizations.

Rosser C, Sager F, Leib S Front Med (Lausanne). 2020; 7:586177.

PMID: 33364246 PMC: 7755134. DOI: 10.3389/fmed.2020.586177.

Do women in science form more diverse research networks than men? An analysis of Spanish biomedical scientists.

Diaz-Faes A, Otero-Hermida P, Ozman M, DEste P PLoS One. 2020; 15(8):e0238229.

PMID: 32853227 PMC: 7451541. DOI: 10.1371/journal.pone.0238229.

Clinical Genome Data Model (cGDM) provides Interactive Clinical Decision Support for Precision Medicine.

Kim H, Kim H, Park Y, Lee W, Lim Y, Kim J Sci Rep. 2020; 10(1):1414.

PMID: 31996707 PMC: 6989462. DOI: 10.1038/s41598-020-58088-2.

References

Simon R, Steinberg S, Hamilton M, Hildesheim A, Khleif S, Kwak L . Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol. 2001; 19(6):1848-54. DOI: 10.1200/JCO.2001.19.6.1848. View

Molidor R, Sturn A, Maurer M, Trajanoski Z . New trends in bioinformatics: from genome sequence to personalized medicine. Exp Gerontol. 2003; 38(10):1031-6. DOI: 10.1016/s0531-5565(03)00168-2. View

Naghavi M, Libby P, Falk E, Casscells S, Litovsky S, Rumberger J . From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003; 108(14):1664-72. DOI: 10.1161/01.CIR.0000087480.94275.97. View

Marincola F . Translational Medicine: A two-way road. J Transl Med. 2003; 1(1):1. PMC: 202357. DOI: 10.1186/1479-5876-1-1. View

Herold B, McArdle P, Stagnaro-Green A . Translational medicine in the first year: integrative cores. Acad Med. 2002; 77(11):1171. DOI: 10.1097/00001888-200211000-00040. View

Mark A, Kelch R . Clinician scientist training program: a proposal for training medical students in clinical research. J Investig Med. 2001; 49(6):486-90. DOI: 10.2310/6650.2001.33624. View

Buxton D, Lee S, Wickline S, Ferrari M . Recommendations of the National Heart, Lung, and Blood Institute Nanotechnology Working Group. Circulation. 2003; 108(22):2737-42. DOI: 10.1161/01.CIR.0000096493.93058.E8. View

Carrel T . The relationship between surgeon and basic scientist. Transpl Immunol. 2002; 9(2-4):331-7. DOI: 10.1016/s0966-3274(02)00008-4. View

Hughes G, Post M, Simons M, Annex B . Translational physiology: porcine models of human coronary artery disease: implications for preclinical trials of therapeutic angiogenesis. J Appl Physiol (1985). 2003; 94(5):1689-701. DOI: 10.1152/japplphysiol.00465.2002. View

10.

Dauphinee D, Martin J . Breaking down the walls: thoughts on the scholarship of integration. Acad Med. 2000; 75(9):881-6. DOI: 10.1097/00001888-200009000-00008. View

11.

Sung N, Crowley Jr W, Genel M, Salber P, Sandy L, Sherwood L . Central challenges facing the national clinical research enterprise. JAMA. 2003; 289(10):1278-87. DOI: 10.1001/jama.289.10.1278. View

12.

Jin P, Wang E . Polymorphism in clinical immunology - From HLA typing to immunogenetic profiling. J Transl Med. 2003; 1(1):8. PMC: 280736. DOI: 10.1186/1479-5876-1-8. View

13.

Gamulin S . Impact of molecular medicine on pathophysiology, medical practice, and medical education. Croat Med J. 2003; 44(4):374-85. View

14.

Naghavi M, Libby P, Falk E, Casscells S, Litovsky S, Rumberger J . From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation. 2003; 108(15):1772-8. DOI: 10.1161/01.CIR.0000087481.55887.C9. View

15.

Kagarise M, Sheldon G . Translational ethics: a perspective for the new millennium. Arch Surg. 2000; 135(1):39-45. DOI: 10.1001/archsurg.135.1.39. View

16.

Earl H . American Society for Clinical Oncology 39th Annual Meeting, Chicago, Illinois, USA, 31 May to 3 June 2003: breast cancer neoadjuvant and adjuvant chemotherapy--prognostic and predictive markers. Breast Cancer Res. 2003; 5(6):289-93. PMC: 314407. DOI: 10.1186/bcr647. View

17.

Howell L, Bertakis K . Clinical faculty tracks and academic success at the University of California Medical Schools. Acad Med. 2004; 79(3):250-7. DOI: 10.1097/00001888-200403000-00012. View

18.

. European Organization for Research and Treatment of Cancer (EORTC) Laboratory Research Division workshop on the role of in vivo pre-clinical models in the development of contemporary cancer therapeutics, Verona, Italy, 3 February 2001. Eur J Cancer. 2001; 37(16):1976-80. DOI: 10.1016/s0959-8049(01)00224-6. View

19.

Granger C, Van Eyk J, Mockrin S, Anderson N . National Heart, Lung, And Blood Institute Clinical Proteomics Working Group report. Circulation. 2004; 109(14):1697-703. DOI: 10.1161/01.CIR.0000121563.47232.2A. View

20.

Leaf C . Why we're losing the war on cancer (and how to win it). Fortune. 2004; 149(6):76-82, 84-6, 88 passim. View